Softbank led the Series C round of funding for Deep Genomics, a startup that applies its artificial intelligence technology to all aspects of discovering and developing new drugs. The Deep Genomics platform has yielded 10 programs; CEO Brendan Frey aims to advance four of them to the clinic in two years, all while tripling the company’s pipeline.
Our latest eBook offers examples of how some of the players in healthcare are thinking about AI, seeking to apply it across care coordination, drug development and early detection of disease and how to address some of the challenges the technology poses for adoption and implementation.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
This week on MedHeads, the FDA cleared GlaxoSmithKline's propeller platform, University of Toronto spinout explores genomics and debates over the status of mobile health.
Deep Genomics, a new University of Toronto spinout, uses artificial intelligence and deep machine learning to try to mimic the way in which the cell works - and predict whether a person will get a disease or not.